A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

clinical trial

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02960906

P6099clinical trial phasephase II clinical trialQ42824440
P17countryFranceQ142
P582end time2020-05-01
P2899minimum age18
P1132number of participants150
P6153research siteCentre François BaclesseQ50036603
Institut Gustave RoussyQ266227
hôpital FochQ3145155
Institut Claudius RegaudQ3151727
L'Institut Mutualiste MontsourisQ3152361
P1813short nameBIONIKK
P580start time2017-05-31
P8363study typeinterventional studyQ78089383
P1476titleA Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer